A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.

Andrea VargaJean-Charles SoriaAntoine HollebecquePatricia LoRussoJohanna BendellShih-Min A HuangMarie-Claire WagleKwame OkrahLichuan LiuElaine Murray Sandra M Sanabria-BohorquezMichael TagenHatem DokainishLars MuellerHoward Burris

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

GDC-0994 had an acceptable safety profile and pharmacodynamic effects were observed by FDG-PET and in serial tumor biopsies. Single-agent activity was observed in 2 patients with BRAF-mutant colorectal cancer.

Keyphrases

pet ct
positron emission tomography
endothelial cells
pet imaging
signaling pathway
computed tomography
wild type
metastatic colorectal cancer